Acumen Pharmaceuticals Stock Technical Analysis
| ABOS Stock | USD 2.48 0.00 0.00% |
As of the 9th of February, Acumen Pharmaceuticals shows the Risk Adjusted Performance of 0.0508, downside deviation of 4.98, and Mean Deviation of 4.38. Acumen Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Acumen Pharmaceuticals variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Acumen Pharmaceuticals is priced correctly, providing market reflects its regular price of 2.48 per share. Please also double-check Acumen Pharmaceuticals total risk alpha, which is currently at (0.30) to validate the company can sustain itself at a future point.
Acumen Pharmaceuticals Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Acumen, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to AcumenAcumen Pharmaceuticals' Momentum analyses are specifically helpful, as they help investors time the market using mark points where the market can reverse. The reversal spots are usually identified through divergence between price movement and momentum.Acumen Pharmaceuticals Analyst Consensus
| Target Price | Consensus | # of Analysts | |
| 7.0 | Strong Buy | 5 | Odds |
Most Acumen analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Acumen stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Acumen Pharmaceuticals, talking to its executives and customers, or listening to Acumen conference calls.
Is there potential for Biotechnology market expansion? Will Acumen introduce new products? Factors like these will boost the valuation of Acumen Pharmaceuticals. If investors know Acumen will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Acumen Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Investors evaluate Acumen Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Acumen Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Acumen Pharmaceuticals' market price to deviate significantly from intrinsic value.
Understanding that Acumen Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Acumen Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Acumen Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.
Acumen Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Acumen Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Acumen Pharmaceuticals.
| 11/11/2025 |
| 02/09/2026 |
If you would invest 0.00 in Acumen Pharmaceuticals on November 11, 2025 and sell it all today you would earn a total of 0.00 from holding Acumen Pharmaceuticals or generate 0.0% return on investment in Acumen Pharmaceuticals over 90 days. Acumen Pharmaceuticals is related to or competes with Inovio Pharmaceuticals, Opus Genetics, Agenus, Alector, Seer, Seres Therapeutics, and Fate Therapeutics. Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treat... More
Acumen Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Acumen Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Acumen Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.98 | |||
| Information Ratio | 0.038 | |||
| Maximum Drawdown | 38.93 | |||
| Value At Risk | (7.89) | |||
| Potential Upside | 9.94 |
Acumen Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Acumen Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Acumen Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Acumen Pharmaceuticals historical prices to predict the future Acumen Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0508 | |||
| Jensen Alpha | 0.2154 | |||
| Total Risk Alpha | (0.30) | |||
| Sortino Ratio | 0.0483 | |||
| Treynor Ratio | 0.2441 |
Acumen Pharmaceuticals February 9, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0508 | |||
| Market Risk Adjusted Performance | 0.2541 | |||
| Mean Deviation | 4.38 | |||
| Semi Deviation | 4.79 | |||
| Downside Deviation | 4.98 | |||
| Coefficient Of Variation | 1913.69 | |||
| Standard Deviation | 6.31 | |||
| Variance | 39.84 | |||
| Information Ratio | 0.038 | |||
| Jensen Alpha | 0.2154 | |||
| Total Risk Alpha | (0.30) | |||
| Sortino Ratio | 0.0483 | |||
| Treynor Ratio | 0.2441 | |||
| Maximum Drawdown | 38.93 | |||
| Value At Risk | (7.89) | |||
| Potential Upside | 9.94 | |||
| Downside Variance | 24.77 | |||
| Semi Variance | 22.97 | |||
| Expected Short fall | (5.00) | |||
| Skewness | 1.81 | |||
| Kurtosis | 7.28 |
Acumen Pharmaceuticals Backtested Returns
Acumen Pharmaceuticals appears to be very risky, given 3 months investment horizon. Acumen Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.0796, which signifies that the company had a 0.0796 % return per unit of risk over the last 3 months. By analyzing Acumen Pharmaceuticals' technical indicators, you can evaluate if the expected return of 0.5% is justified by implied risk. Please makes use of Acumen Pharmaceuticals' Mean Deviation of 4.38, downside deviation of 4.98, and Risk Adjusted Performance of 0.0508 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Acumen Pharmaceuticals holds a performance score of 6. The firm shows a Beta (market volatility) of 1.31, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Acumen Pharmaceuticals will likely underperform. Please check Acumen Pharmaceuticals' value at risk, as well as the relationship between the skewness and day typical price , to make a quick decision on whether Acumen Pharmaceuticals' price patterns will revert.
Auto-correlation | 0.56 |
Modest predictability
Acumen Pharmaceuticals has modest predictability. Overlapping area represents the amount of predictability between Acumen Pharmaceuticals time series from 11th of November 2025 to 26th of December 2025 and 26th of December 2025 to 9th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Acumen Pharmaceuticals price movement. The serial correlation of 0.56 indicates that roughly 56.0% of current Acumen Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.56 | |
| Spearman Rank Test | 0.38 | |
| Residual Average | 0.0 | |
| Price Variance | 0.11 |
Acumen Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Acumen Pharmaceuticals Technical Analysis
The output start index for this execution was one with a total number of output elements of sixty. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Acumen Pharmaceuticals volatility. High ATR values indicate high volatility, and low values indicate low volatility.
About Acumen Pharmaceuticals Technical Analysis
The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of Acumen Pharmaceuticals on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of Acumen Pharmaceuticals based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on Acumen Pharmaceuticals price pattern first instead of the macroeconomic environment surrounding Acumen Pharmaceuticals. By analyzing Acumen Pharmaceuticals's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of Acumen Pharmaceuticals's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to Acumen Pharmaceuticals specific price patterns or momentum indicators. Please read more on our technical analysis page.
| 2025 | 2026 (projected) | Net Debt To EBITDA | 0.0695 | 0.066 | Intangibles To Total Assets | 4.9E-4 | 4.36E-4 |
Acumen Pharmaceuticals February 9, 2026 Technical Indicators
Most technical analysis of Acumen help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Acumen from various momentum indicators to cycle indicators. When you analyze Acumen charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0508 | |||
| Market Risk Adjusted Performance | 0.2541 | |||
| Mean Deviation | 4.38 | |||
| Semi Deviation | 4.79 | |||
| Downside Deviation | 4.98 | |||
| Coefficient Of Variation | 1913.69 | |||
| Standard Deviation | 6.31 | |||
| Variance | 39.84 | |||
| Information Ratio | 0.038 | |||
| Jensen Alpha | 0.2154 | |||
| Total Risk Alpha | (0.30) | |||
| Sortino Ratio | 0.0483 | |||
| Treynor Ratio | 0.2441 | |||
| Maximum Drawdown | 38.93 | |||
| Value At Risk | (7.89) | |||
| Potential Upside | 9.94 | |||
| Downside Variance | 24.77 | |||
| Semi Variance | 22.97 | |||
| Expected Short fall | (5.00) | |||
| Skewness | 1.81 | |||
| Kurtosis | 7.28 |
Acumen Pharmaceuticals February 9, 2026 Daily Trend Indicators
Traders often use several different daily volumes and price technical indicators to supplement a more traditional technical analysis when analyzing securities such as Acumen stock. With literally thousands of different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 0.09 | ||
| Daily Balance Of Power | 0.00 | ||
| Rate Of Daily Change | 1.00 | ||
| Day Median Price | 2.37 | ||
| Day Typical Price | 2.40 | ||
| Price Action Indicator | 0.12 | ||
| Market Facilitation Index | 0.23 |
Additional Tools for Acumen Stock Analysis
When running Acumen Pharmaceuticals' price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.